Payment overview · 2025
General Payments
$1,199.62
57 reported records · 21 companies
Healthcare provider profile · identity verified
Andrew Colman, DO
Allopathic & Osteopathic Physicians|General Practice · WESTLAND, MI · NPI 1912983131
Verified facts
What the public records show
CMS Open Payments records show Andrew Colman, DO received $1,199.62 in general payments during 2025 across 57 reported records.
GlaxoSmithKline, LLC. accounted for 9.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Fanapt, Farxiga, Gemtesa, Linzess, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 918 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Trelegy Ellipta by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 918 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APTIOM as an associated drug or biological on 11 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Aptiom by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Gemtesa by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Austedo by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $114.81 | 9.6% | 7 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $103.47 | 8.6% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $98.98 | 8.2% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $84.11 | 7.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $83.90 | 7.0% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $83.26 | 6.9% | 3 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$80.04 | 6.7% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $72.86 | 6.1% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $68.99 | 5.8% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $55.07 | 4.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.17 | 4.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.50 | 4.2% | 2 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $47.18 | 3.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $43.98 | 3.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.01 | 3.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.92 | 2.8% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $20.64 | 1.7% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $19.53 | 1.6% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $16.31 | 1.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.66 | 1.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.23 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,149.67 | 56 |
| Long term medical supply or device loan | $49.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $127.93 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $114.81 | 7 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $103.47 | 6 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $84.11 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $83.26 | 3 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $83.26 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $80.04 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $68.99 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $50.50 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $50.50 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE INSULINX Normalized: freestyle insulinx |
Device | Abbott Laboratories | $49.95 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $49.03 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $43.98 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $39.85 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.01 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $38.01 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.92 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.11 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.69 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $20.64 | 1 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $19.53 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $16.31 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| SEROQUEL Normalized: seroquel |
Drug | AstraZeneca Pharmaceuticals LP | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 918 | exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 88 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 127 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
918 | 110 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
36 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
127 | 31 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 15 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
918 | 110 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 24 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | APTIOM open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 11 recipient NPIs · example record 1176658319 |
Aptiom · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1207 | 257 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1109 | 168 |
| Eliquis | Apixaban | 918 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 814 | 165 |
| Furosemide | Furosemide | 753 | 135 |
| Lisinopril | Lisinopril | 705 | 144 |
| Gabapentin | Gabapentin | 545 | 92 |
| Metoprolol Tartrate | Metoprolol Tartrate | 526 | 107 |
| Sertraline Hcl | Sertraline Hcl | 515 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 503 | 108 |
| Tamsulosin Hcl | Tamsulosin Hcl | 479 | 102 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 454 | 73 |
| Metformin Hcl | Metformin Hcl | 433 | 81 |
| Omeprazole | Omeprazole | 397 | 109 |
| Potassium Chloride | Potassium Chloride | 397 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 365 | 75 |
| Trazodone Hcl | Trazodone Hcl | 347 | 67 |
| Mirtazapine | Mirtazapine | 343 | 71 |
| Losartan Potassium | Losartan Potassium | 340 | 81 |
| Quetiapine Fumarate | Quetiapine Fumarate | 332 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 287 | 57 |
| Tramadol Hcl | Tramadol Hcl | 281 | 56 |
| Lorazepam | Lorazepam | 256 | 62 |
| Clopidogrel | Clopidogrel Bisulfate | 251 | 55 |
| Buspirone Hcl | Buspirone Hcl | 245 | 43 |
| Levetiracetam | Levetiracetam | 241 | 40 |
| Carvedilol | Carvedilol | 228 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 216 | 53 |
| Donepezil Hcl | Donepezil Hcl | 196 | 44 |
| Simvastatin | Simvastatin | 182 | 40 |
| Warfarin Sodium | Warfarin Sodium | 168 | 17 |
| Jardiance | Empagliflozin | 162 | 31 |
| Allopurinol | Allopurinol | 161 | 41 |
| Olanzapine | Olanzapine | 145 | 29 |
| Baclofen | Baclofen | 144 | 22 |
| Trulicity | Dulaglutide | 142 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 134 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 127 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 123 | 35 |
| Montelukast Sodium | Montelukast Sodium | 123 | 27 |
| Risperidone | Risperidone | 116 | 23 |
| Famotidine | Famotidine | 115 | 28 |
| Latanoprost | Latanoprost | 114 | 26 |
| Divalproex Sodium | Divalproex Sodium | 112 | 24 |
| Spironolactone | Spironolactone | 112 | 26 |
| Aripiprazole | Aripiprazole | 111 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 110 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 108 | 79 |
| Xarelto | Rivaroxaban | 107 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 24 |
| Glipizide | Glipizide | 104 | 16 |
| Memantine Hcl | Memantine Hcl | 101 | 29 |
| Pregabalin | Pregabalin | 100 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 98 | 29 |
| Alendronate Sodium | Alendronate Sodium | 95 | 20 |
| Alprazolam | Alprazolam | 95 | 21 |
| Meloxicam | Meloxicam | 95 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 95 | 18 |
| Atenolol | Atenolol | 94 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 91 | 22 |
| Ezetimibe | Ezetimibe | 91 | 21 |
| Cephalexin | Cephalexin | 88 | 48 |
| Farxiga | Dapagliflozin Propanediol | 88 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 88 | 14 |
| Lactulose | Lactulose | 86 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 84 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 81 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 80 | 33 |
| Amoxicillin | Amoxicillin | 79 | 52 |
| Finasteride | Finasteride | 79 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 26 |
| Myrbetriq | Mirabegron | 77 | 15 |
| Metformin Hcl Er | Metformin Hcl | 76 | 15 |
| Bupropion Xl | Bupropion Hcl | 74 | 11 |
| Midodrine Hcl | Midodrine Hcl | 74 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 74 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 73 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 71 | 15 |
| Prednisone | Prednisone | 71 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 18 |
| Entresto | Sacubitril/Valsartan | 68 | suppressed |
| Januvia | Sitagliptin Phosphate | 68 | suppressed |
| Lamotrigine | Lamotrigine | 67 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 66 | 14 |
| Bumetanide | Bumetanide | 65 | 26 |
| Clonidine Hcl | Clonidine Hcl | 65 | 18 |
| Lacosamide | Lacosamide | 65 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 65 | 13 |
| Lidocaine | Lidocaine | 64 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 60 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 13 |
| Haloperidol | Haloperidol | 59 | 12 |
| Ozempic | Semaglutide | 58 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 39 |
| Digoxin | Digoxin | 55 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 54 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | suppressed |
| Primidone | Primidone | 53 | suppressed |
| Nystatin | Nystatin | 52 | 29 |
| Enalapril Maleate | Enalapril Maleate | 48 | suppressed |
| Humalog | Insulin Lispro | 48 | 19 |
| Propranolol Hcl Er | Propranolol Hcl | 48 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 47 | 15 |
| Clonazepam | Clonazepam | 47 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 47 | 15 |
| Austedo | Deutetrabenazine | 46 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 46 | suppressed |
| Lovastatin | Lovastatin | 44 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 12 |
| Azithromycin | Azithromycin | 41 | 30 |
| Venlafaxine Hcl | Venlafaxine Hcl | 41 | suppressed |
| Carbamazepine | Carbamazepine | 40 | suppressed |
| Lubiprostone | Lubiprostone | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 38 | 15 |
| Rivastigmine | Rivastigmine | 38 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 36 | 36 |
| Novolog | Insulin Aspart | 36 | 12 |
| Ibuprofen | Ibuprofen | 35 | 14 |
| Levofloxacin | Levofloxacin | 35 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 28 |
| Scopolamine | Scopolamine | 35 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | suppressed |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 18 |
| Novolog Flexpen | Insulin Aspart | 33 | 14 |
| Sevelamer Carbonate | Sevelamer Carbonate | 33 | suppressed |
| Topiramate | Topiramate | 33 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 33 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 32 | suppressed |
| Mupirocin | Mupirocin | 32 | 19 |
| Nystop | Nystatin | 32 | 19 |
| Fluconazole | Fluconazole | 31 | 22 |
| Torsemide | Torsemide | 31 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | 13 |
| Ketoconazole | Ketoconazole | 29 | 16 |
| Lagevrio (Eua) | Molnupiravir | 29 | 29 |
| Linzess | Linaclotide | 29 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 29 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 29 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | 16 |
| Cilostazol | Cilostazol | 27 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 18 |
| Benztropine Mesylate | Benztropine Mesylate | 26 | suppressed |
| Fanapt | Iloperidone | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 26 | suppressed |
| Gemtesa | Vibegron | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 12 |
| Methimazole | Methimazole | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 24 |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 23 | 16 |
| Amantadine | Amantadine Hcl | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Anastrozole | Anastrozole | 22 | suppressed |
| Clozapine | Clozapine | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 19 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Loperamide | Loperamide Hcl | 21 | 19 |
| Metronidazole | Metronidazole | 21 | 15 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 21 | 21 |
| Rytary | Carbidopa/Levodopa | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Admelog | Insulin Lispro | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 20 | suppressed |
| Acetylcysteine | Acetylcysteine | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 19 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 19 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Insulin Lispro | Insulin Lispro | 18 | 13 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | 12 |
| Budesonide | Budesonide | 17 | suppressed |
| Calcium Acetate | Calcium Acetate | 17 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Klayesta | Nystatin | 16 | suppressed |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Rufinamide | Rufinamide | 15 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 15 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 15 | suppressed |
| Alogliptin | Alogliptin Benzoate | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Nateglinide | Nateglinide | 14 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Sodium Polystyrene Sulfonate | Sodium Polystyrene Sulfonate | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Konvomep | Omeprazole/Sodium Bicarbonate | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Trospium Chloride | Trospium Chloride | 12 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 11 | suppressed |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Levocarnitine | Levocarnitine | 11 | suppressed |
| Methazolamide | Methazolamide | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,199.62 · 57 records | GlaxoSmithKline, LLC. | AIRSUPRA, ARISTADA, AUSTEDO XR, CAPLYTA, CREON, Cologuard Collection Kit, DAYBUE, ELIQUIS, FANAPT, FARXIGA, FREESTYLE INSULINX, FREESTYLE LIBRE 3, GEMTESA, HETLIOZ, INGREZZA, JATENZO, LINZESS, LYBALVI, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SEROQUEL, TRELEGY ELLIPTA, UBRELVY, VALTOCO, VIBERZI, ZAVZPRET | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error